Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STERLING's PENTAZOCINE IS SHOWING 70% REDUCTION IN ABUSE IN DAWN

Executive Summary

STERLING's PENTAZOCINE IS SHOWING 70% REDUCTION IN ABUSE IN DAWN (Drug Abuse Warning Network) data for the nine-month period April-December, 1983, the company told House Crime Subcmte. Chairman Hughes (D-NJ) in an April 12 letter. Reporting the effect of the new naloxone/pentazocine combo, Talwin-NX, on street abuse patterns, Sterling told the House subcmte. that DAWN reports continue to show a decline in pentazocine mentions. At an FDA meeting last fall, DAWN data for the first six months of Talwin-NX marketing showed an almost 75% reduction in abuse mentions for pentazocine. The updated figures through the end of the year indicate that the reduction in abuse of the chemical is continuing. The Sterling letter to Hughes follows a Feb. 22 Crime subcmte. hearing on drug diversion at which a witness (Robert Weiss, prosecuting attorney for Michigan's Genesee County) testified that addicts were "burning off" the layer of naloxone contained in the reformulated Talwin-Nx in order to eliminate its intended narcotic antagonist effect upon injection ("The Pink Sheet" Feb. 27, p. 3). In the letter to the Hill, Sterling asserts that it "has actively sought, but found no evidence in support of those claims." Sterling further asserted that tests to determine whether abusers can successfully remove naloxone from Talwin-Nx demonstrate that the reformulation is effective. In one study, the firm duplicated the method of "burning off" the naloxone as demonstrated by an abuser, and found that naloxone was present "in the same ratio of 1:100 (naloxone to pentazocine) as exists in the newly formulated tablet." In another study, Sterling found "allegations by addicts that naloxone could be removed by boiling the tablets in water proved to be inaccurate." The company conducted several studies in which they boiled the tablets for 5, 10, 15 and 30 minutes without finding an altered ratio of the two drugs. Sterling further maintains that the tests "confirmed our contention that the reformulated combination of pentazocine and naloxone can not be easily altered for misuse as alleged." The company contends: "Information obtained by various routes, including on-the-spot investigation and discussion with various local enforcement and medical officials from coast to coast, supports our belief that the reformulation is proving effective in curbing the misuse of pentazocine."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel